Annexon, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ANNX Nasdaq 2830 www.annexonbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Annexon, Inc.

With Annexon Up 14%, Insider Buyers Count Their Returns - Dec 11th, 2025 10:52 am
Analyst Confidence Strong in Annexon (ANNX) Amid Vonaprument Advancement - Nov 28th, 2025 11:26 pm
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million - Nov 14th, 2025 2:01 pm
Exploring 3 High Growth Tech Stocks In The US Market - Nov 14th, 2025 10:38 am
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Nov 12th, 2025 8:55 pm
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Nov 12th, 2025 2:12 pm
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - Nov 10th, 2025 2:05 pm
Nuveen Expands Portfolio With Annexon, Inc. (ANNX) Acquisition - Sep 30th, 2025 9:41 am
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? - Sep 7th, 2025 8:18 am
Annexon Biosciences to Participate in Upcoming September Investor Conferences - Aug 27th, 2025 6:00 am
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Aug 18th, 2025 2:05 pm
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - Aug 14th, 2025 2:05 pm
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy - Aug 7th, 2025 2:30 pm
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy - Jul 24th, 2025 5:00 am
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) - Jun 18th, 2025 2:05 pm
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference - May 29th, 2025 2:05 pm
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting - May 19th, 2025 2:05 pm
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - May 16th, 2025 2:05 pm
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - May 12th, 2025 6:00 am
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting - May 9th, 2025 3:00 pm